Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johansson, U.-B.
Right arrow Articles by Lins, P.-E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johansson, U.-B.
Right arrow Articles by Lins, P.-E.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:2025-2027, 2005
© 2005 by the American Diabetes Association, Inc.

Clinical Care/Education/Nutrition
Brief Report

Impaired Absorption of Insulin Aspart From Lipohypertrophic Injection Sites

Unn-Britt Johansson, RN, PHD1,2, Susanne Amsberg, RN2, Lena Hannerz, RN2, Regina Wredling, RN, PHD2,3, Ulf Adamson, MD, PHD2, Hans J. Arnqvist, MD, PHD4 and Per-Eric Lins, MD, PHD2

1 Sophiahemmet University College, Stockholm, Sweden
2 Department of Medicine, Danderyd University Hospital, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
3 Department of Nursing, Karolinska Institutet, Stockholm, Sweden
4 Division of Cellbiology, Department of Biomedicine and Surgery, Faculty of Health Sciences, Linköping University, Linköping, Sweden

Address correspondence and reprint requests to Unn-Britt Johansson, RN, PhD, Sophiahemmet University College, Box 5605, SE-114 86 Stockholm, Sweden. E-mail: unn-britt.johansson@sophiahemmethogskola.se

Abbreviations: AUC, area under the curve

The first 20% of the full text of this article appears below.


   INTRODUCTION
 
Lipohypertrophy is a common side effect of subcutaneous insulin therapy, occurring in up to 50% of patients with type 1 diabetes (1–3). It is generally held that absorption of insulin from such palpably abnormal sites is erratic, although the consequence thereof on glucose control has been considered controversial (1,4,5). Notably, a recent study using the continuous glucose monitoring system to monitor swings of blood glucose documented a significant correlation between the mean of daily differences of glucose and the severity of injection site lipohypertrophy (6). Few studies have investigated insulin uptake from lipohypertrophic tissue. Absorption of isophane (NPH) insulin, as determined by plasma free insulin, was found to be markedly defective at abnormal injection sites (7), and absorption of regular insulin (Actrapid) was delayed as determined by the clearance of 125I-insulin (8). It was concluded from these studies that the differences were of sufficient magnitude to be of clinical importance. Currently, both of these insulin preparations give way to insulin analogs. Therefore, the present study was conducted to investigate whether the absorption of a single subcutaneous dose of insulin aspart is impaired when administered to lipohypertrophic tissue in patients with type 1 diabetes.


   RESEARCH DESIGN AND METHODS
 
Nine male patients (51.6 ± 5.4 years of age [means ± SE; range 22–69], HbA1c 7.3 ± 0.4% [ref. <5.2%], BMI 24.3 ± 1.0 kg/m2, and duration of . . . [Full Text of this Article]


   RESULTS
 

   CONCLUSIONS
 

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.